The virus spread more slowly where vaccination had been practiced for decades
In the long history of medicine, few discoveries arrive as quietly as the realization that an old tool may serve a new purpose. Researchers at St. Petersburg University, after reviewing nearly a hundred studies, have found that nations with decades-long BCG tuberculosis vaccination programs experienced slower Covid-19 spread and lower mortality — while countries without such programs suffered significantly higher death tolls. The mechanism appears to lie in the vaccine's capacity to train the immune system in early childhood, creating a kind of immunological readiness that extends far beyond tuberculosis. The finding does not close a question so much as open one: how much of our resilience against new threats is quietly shaped by interventions we made long ago.
- A century-old tuberculosis vaccine is emerging as an unexpected variable in why Covid-19 killed far more people in some countries than others.
- The geographic divide is striking — nations like China, Japan, India, and Finland, with sustained childhood BCG programs, recorded markedly lower Covid mortality than the United States, Italy, and Belgium, which had none.
- The vaccine appears to prime the innate immune system in early childhood, generating T memory cells that can recognize and mobilize against novel pathogens like the coronavirus decades later.
- Adults who never received BCG as children present a harder problem — late-life vaccination likely offers far weaker protection, though some research hints it may still reduce disease severity.
- Multiple independent research teams across Russia, India, and the Netherlands are converging on similar conclusions, lending the association growing — if still preliminary — credibility.
- The science remains associative rather than causal, and ongoing trials worldwide are working to determine whether this old vaccine can be deliberately deployed as a partial shield against future outbreaks.
Scientists at St. Petersburg University spent months reviewing roughly a hundred academic papers and epidemiological records, searching for patterns in how Covid-19 moved through different populations. Their conclusion, published in the peer-reviewed journal Juvenis scientia, was striking: countries with long-standing BCG childhood vaccination programs showed slower viral spread and lower mortality rates than those without.
The geographic pattern was consistent. Finland, China, Japan, and much of Eastern Europe, Central Asia, and South Asia — all with sustained BCG programs — recorded lower Covid death tolls. The contrast with the United States, Italy, Belgium, and most of Germany was stark. The researchers were careful to frame this as association rather than proof of causation, but called the signal strong enough to warrant serious investigation.
The proposed mechanism centers on trained immunity. BCG, it appears, does more than prepare the body against tuberculosis — it primes the innate and adaptive immune system more broadly, creating a heightened alertness to infectious threats. Study supervisor Leonid Churilov explained that early and prolonged childhood exposure to the vaccine strain produces an adjuvant effect, amplifying the body's capacity to recognize and respond to a range of pathogens, including the coronavirus.
For adults who missed childhood vaccination, the picture is less encouraging. Churilov acknowledged that late-life BCG would likely confer far less protection than a lifetime of immunological memory. Yet Dutch research suggested adult vaccination might still reduce disease severity — a narrow but meaningful possibility for populations that never received the shot as children.
Other researchers have arrived at similar findings independently. Scientists at India's ICMR National Institute for Research in Tuberculosis found BCG could boost trained immunity in older adults. Dr. Gobardhan Das of JNU described the cellular mechanism: childhood BCG generates T memory cells that, when coronavirus later enters the body, activate and trigger the production of Covid-specific immune responses — potentially conferring durable protection.
India, with its long-standing national BCG program, sits in a potentially advantageous position within this research landscape. But the science remains preliminary. What the accumulating evidence quietly suggests is that an intervention designed a century ago to fight one disease may carry consequences for another — a reminder that the immune system holds lessons we are still learning to read.
Researchers at St. Petersburg University have spent months combing through roughly a hundred academic papers and epidemiological records, looking for patterns in how Covid-19 moved through different populations. What they found was striking: the virus spread more slowly, and killed fewer people, in countries where the BCG vaccine—a tuberculosis shot given to children for decades—was part of routine childhood immunization. The study, published in the Russian peer-reviewed journal Juvenis scientia, adds another piece to a growing body of research suggesting that an old vaccine might offer unexpected protection against a new disease.
The pattern the St. Petersburg team identified was geographically consistent. In Finland, China, and Japan, as well as across Eastern Europe, Central Asia, South Asia, and Africa, countries with long-standing BCG vaccination programs showed lower Covid mortality rates. The contrast with nations that never adopted the vaccine or abandoned it more than two decades ago was stark. The United States, Italy, the Netherlands, Belgium, and most of Germany—areas without sustained BCG campaigns—recorded significantly higher death tolls from the virus. The researchers framed this not as proof of causation but as a clear association worth investigating further.
The mechanism, according to the St. Petersburg scientists, lies in how the BCG vaccine trains the immune system. The shot doesn't just prepare the body to fight tuberculosis. It appears to prime what researchers call the innate and adaptive immune response—a kind of immunological memory that makes the body more alert and more effective when facing other infectious threats, including the coronavirus. The effect seems strongest when the vaccine is given early in life, during the years when the immune system is still developing. Leonid Churilov, who supervised the study, explained that this early and prolonged exposure to the vaccine strain creates an adjuvant effect, essentially amplifying the body's ability to recognize and respond to various pathogens.
But the picture becomes murkier for adults who missed the vaccine in childhood. Churilov acknowledged that late-life BCG vaccination would likely offer far less protection than the lifelong benefit conferred by childhood immunization. Yet he also noted that research from the Netherlands—a country without routine childhood BCG—suggested that even adult vaccination might not worsen disease outcomes and could potentially reduce severity. This nuance matters because it opens a door, however narrow, for populations that never received the vaccine as children.
Other researchers have reached similar conclusions through different routes. In October, scientists at the ICMR National Institute for Research in Tuberculosis found that BCG vaccination could boost trained immunity in older adults, potentially offering some Covid protection. Dr. Gobardhan Das, a molecular medicine professor at JNU and an early advocate for exploring BCG's role against Covid, explained the mechanism in cellular terms: when the BCG vaccine is administered in childhood, it generates T memory cells—immune cells that retain information about threats they've encountered. When coronavirus later enters a BCG-vaccinated person, those innate memories activate, triggering the production of Covid-specific T cells. This cascade could generate lasting immunity against future coronavirus exposure.
India occupies a particular position in this research landscape. The country has maintained BCG vaccination as part of its national immunization program for children, making it one of the populations the St. Petersburg researchers identified as potentially protected. Yet the research remains preliminary. The St. Petersburg study identified associations, not definitive proof. Other investigations are ongoing in laboratories and clinics around the world. What the accumulating evidence suggests is that an intervention designed a century ago to fight one disease may have unexpected consequences for another—a reminder that the immune system operates in ways we are still learning to read.
Citações Notáveis
This vaccination itself, given in early childhood, changes the immune system in such a way that the new coronavirus disease course tends to be less severe— St. Petersburg University researchers
There is reason to believe that in adults and elderly people who were not vaccinated in early childhood, the effect of late vaccine administration will be significantly less— Leonid Churilov, study supervisor
A Conversa do Hearth Outra perspectiva sobre a história
Why would a tuberculosis vaccine have any effect on a respiratory virus that didn't exist when the vaccine was designed?
The BCG vaccine doesn't just train the immune system to recognize TB. It appears to wake up the entire immune response—making it more alert and more aggressive against threats in general. It's like putting the body on higher alert.
So if that's true, why isn't every country using it against Covid?
Because the protection seems to depend on timing. If you got the vaccine as a child, decades ago, your immune system has been primed all your life. If you're an adult who never got it, a single shot now probably won't do much. The window closes.
But the Netherlands study suggested even adults might benefit?
Yes, and that's the hopeful part. It suggests the benefit isn't zero for latecomers, just smaller. But we're still in the territory of associations and mechanisms, not certainty.
What does this mean for countries like the US that stopped BCG vaccination?
It means those populations may be more vulnerable to severe Covid, at least according to this data. Whether that's the whole story or just one factor among many—that's still being worked out.
So this is one more reason to keep childhood vaccination programs running?
It's one more piece of evidence that what we do to children's immune systems early on echoes through their entire lives.